SUMMARY
The aim of this study was to determine the critical care and associated hospital costs for 2009 influenza A/H1N1 patients admitted to intensive care units (ICU) in Australia and New Zealand during the southern hemisphere winter. All 762 patients admitted to ICUs in Australian and New Zealand between 1 June and 31 August 2009 with confirmed 2009 H1N1 influenza A were included. Costs were assigned based on ICU and hospital length-ofstay, using data from a single Australian ICU which estimated the daily cost of an ICU bed, along with published costs for a ward bed. Additional costs were assigned for allied health, overheads and extracorporeal membrane oxygenation services. The median (interquartile range) ICU and total hospital costs per patient were AU$35,942 ($10,269 to $82,152) and AU$51, 294 ($22, 849 to $110, 340) respectively, while the mean (standard deviation) ICU and total hospital costs per patient were AU$63,298 ($78,722) and AU$85, 395 ($147, 457) , respectively. A multivariate analysis found death was significantly associated with a reduction in the log of total costs, while the use of mechanical ventilation and ICU admission with viral pneumonitis/acute respiratory distress syndrome or secondary bacterial pneumonia were significantly associated with an increase in the log of total costs. The cost of 2009 H1N1 patients in ICU was significantly higher than the previously published costs for an average ICU admission, and the total cost of treating 2009 H1N1 patients in ICU admitted during winter 2009 was more than $65,000,000. and associated hospital costs for 2009 H1N1 patients admitted to ICUs in Australia and New Zealand. In addition, we updated the previously published data on mortality for patients with 2009 H1N1 who were admitted to ICUs in Australia and New Zealand 2 .
METHODS

Study design
We performed a multicentre inception cohort study in 187 ICUs, comprising all adult and paediatric ICUs in Australia and New Zealand. The methodology for this study has been published previously 2 . In brief, we identified all patients admitted to ICU with confirmed 2009 H1N1 influenza A between 1 June and 31 August 2009. Data collected for each patient included demographics, comorbidities, for women whether pregnant or postpartum <28 days, hospital and ICU admission and discharge dates, presence and type of influenza syndrome, daily use of mechanical ventilation, extracorporeal membrane oxygenation (ECMO), renal replacement therapy and vasopressors, and ICU and hospital outcome. Each centre obtained institutional ethics committee approval and the requirement for informed consent was waived at all sites.
In our previous report the outcome data were censored at 7 September 2009, and included a cohort of 722 patients 2 . We completed data collection and updated the case ascertainment following the original censor date, and identified a final cohort of patients with confirmed 2009 H1N1 admitted to ICUs in Australia and New Zealand between 1 June and 31 August 2009. The data for this cohort were censored on 23 November 2009.
Unit costs
Within Australia there are limited data available regarding the costs associated with critical care medicine. The daily ICU costs reported here are based on recent data from the Royal Brisbane and Women's Hospital (RBWH), a 986-bed general, tertiary-referral teaching hospital based in Brisbane, Queensland. The RBWH has a closed intensive care unit with 30 beds, of which 22 are ventilated. The methods and data elements included here are the same as described in Rechner and Lipman 4 . The same prospectively designed spreadsheet from which they published the direct costs of an ICU bed and the cost drivers thereof, using data for the 2002/2003 financial year, was updated using data from 1 June to 31 August 2009. The costs were broken down into staffing costs (medical and nursing), clinical support services (such as radiology and pathology), consumables (such as medications, clinical supplies, nonclinical supplies, catering) and capital equipment costs ( Table 1) .
The RBWH does not provide ECMO, a treatment administered to patients with 2009 H1N1 in Australia and New Zealand 5 . No published sources of the cost of ECMO in Australia and New Zealand exist, so we calculated the cost of ECMO using a groundup costing method including transport, consumables, labour, pathology and capital equipment costs. We obtained information on consumables (number of circuits and cannulae used, blood products received) and the method of retrieval for patients who were transferred to a centre that provides ECMO services from an observational study of all 2009 H1N1 patients treated with ECMO in Australia and New Zealand 5 , as shown in Table 2 . We obtained information on the additional staffing requirements for patients receiving ECMO directly from the ICUs that provided ECMO services during the pandemic. The costs associated with each of the ECMO components are shown in Table 3 . Due to the recent publication of a randomised controlled trial and economic evaluation of ECMO in the United Kingdom (UK) 6 , we also calculated the cost of ECMO using data from the critical care unit expenditure study conducted alongside the randomised controlled trial 7 . This study found that the daily cost of ICU was (in 2003/2004), on average, 77% higher for patients on ECMO compared to those not receiving ECMO 7 .
The critical care cost data from RBWH did not include allied healthcare costs or overheads (such as salary processing, cleaning, power and communication systems, and hospital management), and therefore we added these to the estimates of the daily cost per H1N1 patient in ICU (Table 1) . We included an additional 2.7% for allied health costs, based on findings from a recent UK ICU microcosting study 8 . This equated to 2.5 hours of allied health treatment (such as physiotherapy, social work, dietetics, speech pathology) per day in intensive care 9 . We added an extra 18.5% for overheads, which was the value of overheads for the most common critical care Australian Refined Diagnostic Related Group in the 2007/2008 Australian National Hospital Cost Data Collection Cost Report (AR-DRG A06Z Tracheostomy or Ventilation >95 hours) 10 .
To determine the total hospital cost for patients, we calculated additional costs for the hospital stay following discharge from ICU using published data from Australia's National Hospital Cost Data Collection Cost Report 10 .
We present costs from the perspective of the healthcare provider in 2009 Australian dollars (AU$). As blood products are centrally funded through the National Blood Service in Australia, we did not include the cost of blood products in this study.
Data management and statistical methods
We collected data using electronic case report forms. When the same patient was transferred between ICUs, the data for the multiple admissions were combined. We made no assumptions for missing data, and calculated all proportions as percentages of available data.
We calculated the critical care and associated costs for five subgroups of patients: a) patients who died; b) patients with comorbidities (defined as any Acute Physiological and Chronic Health Evaluation III comorbidity for adults or, for patients under 16 years, defined as prematurity, immunodeficiency, cystic fibrosis, congenital heart disease, neuromuscular disorder or chronic neurological impairment); c) patients who were admitted to ICU with viral pneumonitis/acute respiratory distress syndrome (ARDS) due to 2009 H1N1 influenza; d) pregnant and post-partum women; and e) patients requiring ECMO.
We performed statistical analysis using SAS version 9.1 (SAS Institute, Inc., Cary, NC, USA). We report continuous variables as means with standard deviations (SD) or medians with interquartile ranges (IQR) as appropriate, and categorical variables as percentages with 95% confidence intervals (CI). We performed univariate analysis for differences in costs between groups using t-tests or Wilcoxon rank sum tests as appropriate. Total costs were found to be well approximated by a log-normal distribution, so were log-transformed prior to analysis. We performed multivariate linear regression analysis to identify factors independently associated with logtransformed hospital costs. We included age as a continuous variable in the model and the following as categorical variables: the presence or absence of pregnancy; hospital survival; the presence or absence of any comorbidity; ventilation status; race or ethnic group; and the type of influenza syndrome. A two-sided P value of less than 0.05 was considered to indicate statistical significance, except in the multivariate model, where a P value of less than 0.01 was used to increase the robustness of the model.
RESULTS
A total of 762 patients with confirmed 2009 H1N1 influenza A were included in the cohort. The demographic data for the patients in the cohort are presented in Table 4 .
The median (IQR) ICU length of stay was seven days (3 to 16 days), and the median (IQR) hospital length of stay was 15.5 days (8 to 31 days) ( Figure 1 ). Of the patients with available data, a total of 63% The ICU and hospital costs for the various subgroups of patients are shown in Table 5 . There were no significant differences in cost between survivors and non-survivors, or between pregnant (including postpartum) women and the rest of the cohort. Treatment costs were lower for patients with a pre-existing comorbidity compared to those without a comorbidity (ICU costs AU$25,673 vs AU$46,211, P <0.001) and they had a significantly shorter ICU length of stay (LOS) (5 vs 9 days). Treatment costs were higher for patients admitted to ICU with viral pneumonitis/ARDS compared to those admitted with other influenza syndromes (ICU costs AU$56,479 vs AU$20,538, P <0.001). Treatment costs for patients who received ECMO were more than five times those for whom no ECMO was received (ICU costs AU$160,735 vs AU$30,807, P <0.001).
The multivariate regression analysis showed that death before hospital discharge was associated with a significant reduction in the log of total costs, while admission to ICU with viral pneumonitis/ ARDS or secondary bacterial pneumonia, and mechanical ventilation were associated with a significant increase in the log of total costs. 
DISCUSSION
We have documented the costs of critical care services and associated hospital costs for patients with 2009 A/H1N1 influenza who were admitted to intensive care in Australia and New Zealand. We found a median cost of AU$35,942 and a mean cost of AU$63,298 for treatment in the ICU for patients admitted with 2009 H1N1. This corresponds to a total cost of AU$65,071,106 for ICU treatment for the cohort of 762 patients.
The mean cost of 2009 H1N1 patients in ICU was substantially higher than the average cost of AU$13,655 (indexed to 2009 values) that has been reported 4 . The increase in costs may be explained by the longer LOS (average 12.2 vs 3.7 days, median 7 vs 1.1 days) of the 2009 H1N1 patients, and the use of ECMO. The mean total hospital cost of AU$85,395 was significantly greater than the average cost of a hospital admission in Australia of AU$4199 (indexed to 2009 values) 11 . A recent UK study found that the median total ICU cost in a mixed medical/surgical ICU was €10,916 (AU$18,776, 1€=AU$1.72) and the mean cost was €20,487 (AU$35,238) 8 . These costs are substantially lower than the costs in our study, with our patients having a significantly longer LOS (median 7 vs 2.9 days). One major difference between our study and the UK study is that we did not include the cost of blood products. We did not collect data on the use of blood products in our overall cohort, however ECMO patients received a large volume of blood -a median of 1578 ml of packed red blood cells, 920 ml of fresh frozen plasma and 1411 ml of platelets. The UK microcosting study found that blood products accounted for 9.8% of the total ICU cost, and therefore our costs may underestimate the true cost.
Unexpectedly, we found patients with a preexisting comorbidity had significantly lower costs than those without any comorbidities. This result may be explained by the fact that patients with comorbidities had a significantly shorter LOS, in part due to a higher ICU mortality rate (21.5% vs 10.8%, P <0.001). When adjusting for mortality in the multivariate analysis, the presence of pre-existing comorbidities did not have a significant effect on the log of costs. We also found that patients admitted with viral pneumonitis/ARDS due to 2009 H1N1 influenza had a significantly longer LOS (median 19 vs 12 days) and significantly higher treatment costs compared to those admitted to ICU with other influenza syndromes. There was, however, no significant difference in the mortality rate between patients admitted with viral pneumonitis/ARDS due to 2009 H1N1 influenza and those admitted with other influenza syndromes (17.3% vs 15.3%).
It is likely that we have underestimated the true cost of ECMO during the pandemic as we did not account for increased use of medications, radiology and allied health, nor did we account for the medical time associated with initiation and removal of ECMO. However, using the data from the multicentre study of critical care expenditure conducted concurrently with a randomised controlled trial of ECMO (the CESAR trial) in the UK 7 did not result in a significant change to the costs.
Any inferences drawn from this costing study are subject to limitations. First, our data were collected early in the pandemic and prior to the introduction of a vaccine. Future waves of infection may differ significantly from our cohort in relation to factors that influence cost, such as LOS. In addition, due to resource requirements, we were unable to perform a detailed patient level costing and had to rely on pre-existing Australian ICU cost data. These data were from a single centre and the costs may not be representative of ICU costs in other units. Critical care costs are known to differ between units due to different unit characteristics such as size, staffing, treatment policies and research and training activities 12 . Our patient group had higher ventilation rates (88.9% vs 57.2%) and higher renal replacement therapy rates (18.7% vs 3.6%) than the RBWH cohort from which our costs were derived. As both ventilation and renal replacement therapy have been shown to be associated with increased costs in intensive care 13, 14 , our costs may underestimate the true costs.
In conclusion, we have determined the critical care and hospital costs associated with 2009 H1N1 patients admitted to intensive care in Australia and New Zealand. These costs were higher than those for the average intensive care patient. While the 2009 pandemic was mild in terms of overall health impacts, ICU admissions associated with H1N1 had not only a high mortality rate but a long LOS, resulting in high costs per patient and capacity problems in ICU. The total cost in this particular pandemic was not high due to the relatively low incidence of admission to hospital. The experience suggests however, that a future influenza pandemic, with even a moderately higher hospital admission rate, could have substantial health care costs because of the high unit costs of H1N1 ICU admissions. Healthcare providers need to be aware of the increased funds required to enable effective management of critically ill patients during possible future influenza pandemics.
